诊断标准差异掩盖妊娠期甲状腺疾病的真实患病率:系统综述与荟萃分析
使用TSH第97.5百分位作为上限时,合并患病率分别为临床甲减0.50%、亚临床甲减3.47%、单纯低甲状腺素血症2.05%;甲状腺功能亢进患病率随筛查时机变化。结论认为基于人群的孕期特异性TSH切点可提高诊断准确性并更准确估计患病率。
要点
- 孕期甲状腺疾病患病率报道差异大,源于诊断标准、碘状态和筛查孕周不同
- 采用TSH第97.5百分位切点时,亚临床甲减合并患病率为3.47%
- 甲亢患病率随筛查时机变化,孕早期高于孕中期
核心结论
- 基于人群的孕期特异性TSH切点诊断甲状腺功能减退症可提高诊断准确性并更准确估计患病率。
- 妊娠期甲状腺功能亢进患病率随筛查时机变化。
- 本研究报道的患病率是迄今为止对妊娠期甲状腺疾病真实患病率的最佳估计。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed数据库及相关综述参考文献。
- 研究按甲状腺功能减退诊断的TSH切点和甲状腺功能亢进筛查时机进一步分类。
- 采用随机或固定效应模型(原文未明确)进行荟萃分析得出合并患病率。
- 对使用TSH第97.5百分位切点的研究进行亚组分析。
主要发现
- 使用TSH第97.5百分位作为上限的研究中,临床甲减合并患病率为0.50%。
- 使用TSH第97.5百分位作为上限的研究中,亚临床甲减合并患病率为3.47%。
- 使用TSH第97.5百分位作为上限的研究中,单纯低甲状腺素血症合并患病率为2.05%。
- 孕早期和孕中期临床甲亢合并患病率分别为0.91%和0.65%。
- 孕早期和孕中期亚临床甲亢合并患病率分别为2.18%和0.98%。
关键数值与推荐
- 甲状腺功能减退诊断采用TSH第97.5百分位作为上限时,合并患病率分别为临床甲减0.50%、亚临床甲减3.47%、单纯低甲状腺素血症2.05%。
- 孕早期临床甲亢合并患病率为0.91%,亚临床甲亢为2.18%。
- 孕中期临床甲亢合并患病率为0.65%,亚临床甲亢为0.98%。
临床怎么用
- 临床诊断妊娠期甲状腺功能减退症时应采用基于人群的孕期特异性TSH切点(如第97.5百分位)以提高诊断准确性。
- 解读妊娠期甲状腺疾病患病率时需考虑诊断标准、碘状态和筛查孕周的差异。
- 筛查妊娠期甲状腺功能亢进时应注意筛查时机对患病率估计的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The reported prevalence of thyroid disease in pregnancy varies widely through the published literature. These discrepancies are due to differences in criteria for euthyroidism, nationality, iodine status, and gestational age at screening. As a result, currently, an accepted rate of prevalence does not exist for the various thyroid diseases in pregnancy. Understanding the true prevalence rates of these disorders has important implications for clinical management and the ongoing discussion regarding universal screening. The aims of this study were to assess (i) the true prevalence of thyroid disorders in pregnancy and (ii) the impact of diagnostic methodology on these rates. METHODS: A systematic review was conducted of the existing literature, including the Pubmed database and references from relevant review articles. Sixty-three studies reporting prevalence of overt hypothyroidism, subclinical hypothyroidism, isolated hypothyroxinemia, subclinical hyperthyroidism, and overt hyperthyroidism in pregnant women were included. Studies were further classified by thyrotropin (TSH) cutoff for diagnosis in hypothyroid disease and timing of screening for hyperthyroid disease. Meta-analysis yielded pooled prevalence rates, with subgroup analyses for TSH cutoff and timing of screening. Analysis of studies using the 97.5th percentile TSH cutoff was assessed to yield the most accurate prevalence rates for hypothyroidism. RESULTS: Pooled prevalence rates for hypothyroidism calculated from studies using the 97.5th percentile as an upper limit for TSH were 0.50% for overt hypothyroidism, 3.47% for subclinical hypothyroidism, and 2.05% for isolated hypothyroxinemia. Pooled prevalence rates in the first and second trimesters for hyperthyroidism were 0.91% and 0.65%, respectively, for overt hyperthyroidism and 2.18% and 0.98%, respectively, for subclinical hyperthyroidism. CONCLUSION: Population-based, trimester-specific TSH cutoffs for diagnosis of hypothyroid disease in pregnancy result in more accurate diagnosis and better estimates for prevalence of disease. Prevalence of hyperthyroidism in pregnancy varies depending on timing of screening. The prevalence rates reported in this study represent the best estimate to date of the true rates of thyroid disease in pregnancy.
引用
- Dong AC, Stagnaro-Green A. Differences in Diagnostic Criteria Mask the True Prevalence of Thyroid Disease in Pregnancy: A Systematic Review and Meta-Analysis. Thyroid. 2018. PMID: 30444186. doi:10.1089/thy.2018.0475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。